pharmaphorum

AUGUST 28, 2020

But the advent of COVID-19 is proving to be something of a coming of age for digital epidemiology, which has been putting data from disparate sources to global use for the last 15 years. With COVID-19, it’s pretty commonplace to have that kind of data, but 10 years ago it wasn’t necessarily the case,” he said.

Hospitals 65

Hospitals 65

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. There is no easy answer to the question of how to incentivise innovation without restricting access.

Vaccines 52

Vaccines 52

pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S.

Drug Development 52

Drug Development Immunity Immunization Hospitals 52

pharmaphorum

NOVEMBER 19, 2021

The race to find and bring vaccines to market to fight Covid was impressive. It’s been almost a year since the first Covid vaccine was authorised for use. The mRNA jab, developed by Pfizer and BioNTech, launched to huge fanfare in December 2020 and promised the start of the end of the coronavirus pandemic.

Vaccines 135

Vaccines Communication 135

European Pharmaceutical Review

JULY 11, 2022

Many current COVID-19 vaccine candidates work by presenting fragments of the SARS-CoV?2 2 is the virus that causes COVID-19.). These coronavirus RBDs are attached to a nanoparticle by protein tags, enabling the structure to display fragments from multiple viruses on a single nanoparticle. . The novel vaccine?is

Vaccines 93

Vaccines Immunity Immunization 93

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. These will all help pay for New Science. . Success requires a future-fit enterprise .

Vaccines 90

Vaccines 90

pharmaphorum

FEBRUARY 26, 2021

COVID and beyond. J&J’s size meant that it had the resources to bring to bear against COVID-19 as the pandemic ravaged the world in 2020 and 2021, and the company soon began work on its own vaccine in partnership with the US government. And at the tail end of 2020, a $6.5

Vaccines 124

Vaccines Biosimilars Labelling Diabetes 124

STAT

DECEMBER 15, 2023

million price tag is nearly $1 million higher than its rivals’, even though its own treatment has a serious safety warning about a blood cancer risk. Pfizer overestimated future demand for its pandemic products. But Bluebird’s $3.1 And Pfizer’s other products, no matter how promising, could not close the gap.

240

240

European Pharmaceutical Review

DECEMBER 27, 2023

This round-trip shipping was especially challenging during the early days of the COVID-19 pandemic, which coincided with initial attempts to establish CAR T-cell therapies in daily practice. This is in addition to its considerable price tag.

Adverse Reactions 83

Adverse Reactions Immunity Immunization Medical Schools 83

Pharmaceutical Technology

NOVEMBER 30, 2022

Furthermore, an increase in a sedentary lifestyle, partly brought on by the Covid-19 pandemic, saw a further rise in the obese population. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. compared to a 5.1%

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

Furthermore, an increase in a sedentary lifestyle, partly brought on by the Covid-19 pandemic, saw a further rise in the obese population. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. compared to a 5.1%

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98

Pharmaceutical Technology

MARCH 17, 2023

In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”. Watt explained that for newer, first-in-class drugs these types of agreements can also give healthcare systems safety in their decisions to approve certain drugs. Click here to watch this webinar and access the presentation.

Communication 102

Communication Pharmaceutical Companies Pharmaceutical Companies 102